🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#News: Bayer announces positive topline data from first pivotal PIII study for hotflashes caused by adjuvant endocrine therapy in women with breast cancer: spr.ly/6010a6ZRm

#News: Positive topline results of pivotal Phase III studies in MRI. Learn more: spr.ly/6011a1y1h

#News: Bayer and BlueRock Therapeutics are taking a significant step forward in the fight against Parkinson's disease with the planned initiation of a Phase III clinical trial for an investigational stem cell derived therapy. Learn more: bayer.com/media/en-us/

#NEWS: #TeamBayer is excited to share the latest progress in our pharmaceutical growth strategy and pipeline at #JPM2025. We are focused on addressing the most significant unmet needs for patients globally through industry-leading scientific innovation: spr.ly/6012aneVw

In der ersten Folge „Keine Demokratie ohne Erinnerung“ begrüßen wir als Gast Matthias Berninger Matthias Berninger von Bayer AG , der über die Aufarbeitung der eigenen Unternehmensgeschichte spricht. Einen Überblick zum Forschungsstand zu Unternehmen während der NS-Zeit gibt Andrea

#NEWS: Bayer submitted EU-application for treatment intervals of up to 6-months in wet age-related macular degeneration and diabetic macular edema. Learn more: spr.ly/6012IPYJp

#News: New treatment option for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) receives EU approval. Learn more: spr.ly/6018IXoSA

#News: Investigational Gene therapy for Parkinson’s disease receives RMAT designation. We are proud to be the first company granted RMAT designation both in gene therapy with AskBio Inc. (AskBio) and cell therapy with BlueRock Therapeutics. Learn more: spr.ly/6019I0fU3

By 2050, climate change could cut farmers' harvests by 17% and arable land by 20%. #TeamBayer is tackling this with our Crop Key approach, using biology, chemistry, and #AI to target pests effectively and safely. #RegenerativeAgriculture #CropProtection

.Bayer AG CEO Bill Anderson has infused a startup feel into the 161-year-old German pharmaceutical firm. On this week's episode of #LeadershipNext, Anderson speaks to Fortune's Diane Brady and Kristin Stoller about the current state of the health care system, the U.S. regulatory

The burden of neurological disorders impacts millions of patients and is set to rise during the next decades. We are excited to present results of a pivotal Phase III study in MRI focusing on detecting pathologies of the central nervous system: bayer.com/en/media-overv…

Bayer achieved its adjusted guidance for the Full Year 2024 and takes decisive action to tackle challenges in 2025. See more in our latest press release: spr.ly/6014Lvo46

Earlier today, we published our Full Year 2024 results. CEO Bill Anderson provides a 90-second overview of the figures from 2024 and a look ahead to 2025:

Ending hunger is central to our mission at Bayer. Our CEO, Bill Anderson, and Zambia's President, Hakainde Hichilema, have opened our new maize seed facility in Zambia 🇿🇲 , which aims to improve #foodsecurity for 30 million people and empower smallholder farmers across Africa.

+++ A landmark launch year for Bayer Pharmaceuticals +++ Today, at our annual Pharma Media Day, we unveiled key advancements in our long-term growth strategy. #TeamBayer #PharmaMediaDay #PMD25

#NEWS: Bayer submits a marketing authorization application in Japan for an eye medication with long dosing intervals for the treatment of patients with macular edema following retinal vein occlusion. Learn more: spr.ly/6049FUXth

First-quarter performance: Bayer confirms 2025 targets after solid start to the year. Check our press release for more information: bayer.com/media/en-us/ba…

Earlier today, we published our Q1 2025 results. Our CEO Bill Anderson provides a 90-second overview of the figures from the first quarter and a look into the rest of 2025:

#NEWS: EU recommendation for an eye drug with long dosing intervals for the treatment of (wet) age-related macular degeneration and diabetic macular edema. Learn more: bayer.com/en/media-overv…

Bayer to present for the first time detailed data from the first pivotal PIII study for menopause symptoms in women with breast cancer at ASCO 2025 which have been also published in NEJM: bayer.com/media/en-us/ #TeamBayer #HealthForAll #HungerForNone